SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Algorithm to identify non-alcoholic steatohepatitis (NASH) patients with a NAS≥4 and F≥2: algorithm derived in an American screening cohort and validation in a British non-alcoholic fatty liver disease (NAFLD) cohort- Celine FournierView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018What is needed to link device approval to clinical application approval?- David Litwack, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Serum markers of collagen formation are associated with the severity of Liver fibrosis and Non-Alcoholic Steatohepatitis (NASH) histological features and to impaired renal function (IRF) in a NAFLD cohort- Samuel DanielsView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018A Context of Use Framework for Bioanalytical Validation of the CK18 Apoptosis Biomarker for NASH Drug Development- Sumit KarView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Defining the reference standard for biomarker development - Histology versus clinical outcomes- Kathleen Donohue, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Case definitions for use as reference standards- Mohammed Siddiqui, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Quality standards for imaging studies- Claude Sirlin, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Reporting standards: STARD & TRIPOD- Patrick Bossuyt, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Linking “intended use” to evidence needed for bringing a biomarker to market- John Sninsky, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Repeatability, reproducibility and analytic standards for biomarker development- Abbas BandukwalaView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Pathways and priorities for biomarker assessment- Peter Stein, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2018Integrating science, logistics and cost in approval of hierarchical testing strategies for NASH - The payer's perspective- Robert LoNigro, MDView Slideset
